Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Laura Massarenti, Trine A. Knudsen, Christian Enevold, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Claus Henrik Nielsen, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 3862–3863.

https://doi.org/10.1182/blood-2022-157936

Published: 2022

Journal Articles

Effects of Rituximab and Dexamethasone on Regulatory and Pro-Inflammatory B-Cell Subsets in Patients with Primary Immune Thrombocytopenia

Sif Gudbrandsdottir, MD PhD, Marie Brimnes, PhD, Tania Kollgaard, PhD, Hans Carl Hasselbalch, MD Professor, DMSc, Claus Henrik Nielsen, MD Professor, DMSc

Blood (2016) 128 (22): 1378.

https://doi.org/10.1182/blood.V128.22.1378.1378

Published: 2016

Journal Articles

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Stine Ulrik Mikkelsen, MD, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Mads Emil Bjørn, MD PhDStudent, Christen Lykkegaard Andersen, MD PhD, Ole Weis Bjerrum, MD DMSc, Nana Brochmann, MD PhDStudent, Daniel El Fassi, MD PhD, Torben A Kruse, Professor, PhD, Thomas Stauffer Larsen, MD PhD, Torben Mourits-Andersen, MD, Claus Henrik Nielsen, MD Professor, DMSc, Niels Pallisgaard, MSc, Mads Thomassen, MSc, PhD, Hans Carl Hasselbalch, MD Professor, DMSc

Blood (2015) 126 (23): 824.

https://doi.org/10.1182/blood.V126.23.824.824

Published: 2015

Journal Articles

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Sif Gudbrandsdottir, Henrik Sverre Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov-Jessen, Hans Carl Hasselbalch

Blood (2013) 121 (11): 1976–1981.

https://doi.org/10.1182/blood-2012-09-455691

Published: 2013

Includes: Supplemental data

Journal Articles

Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Is a Dominant Anti-Cytokine Activity in Human IgG Preparations

Morten Svenson, Morten Bagge Hansen, Christian Ross, Marcus Diamant, Klaus Rieneck, Henrik Nielsen, Klaus Bendtzen

Blood (1998) 91 (6): 2054–2061.

https://doi.org/10.1182/blood.V91.6.2054

Published: 1998

Journal Articles

Increased In Vivo Antibody Activity Against Interferon α, Interleukin-1α, and Interleukin-6 After High-Dose Ig Therapy

Christian Ross, Morten Svenson, Henrik Nielsen, Charlotte Lundsgaard, Morten Bagge Hansen, Klaus Bendtzen

Blood (1997) 90 (6): 2376–2380.

https://doi.org/10.1182/blood.V90.6.2376

Published: 1997

NARROW

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Effects of Rituximab and Dexamethasone on Regulatory and Pro-Inflammatory B-Cell Subsets in Patients with Primary Immune Thrombocytopenia

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Is a Dominant Anti-Cytokine Activity in Human IgG Preparations

Increased In Vivo Antibody Activity Against Interferon α, Interleukin-1α, and Interleukin-6 After High-Dose Ig Therapy

Email alerts

ASH Publications

American Society of Hematology

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Effects of Rituximab and Dexamethasone on Regulatory and Pro-Inflammatory B-Cell Subsets in Patients with Primary Immune Thrombocytopenia

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Is a Dominant Anti-Cytokine Activity in Human IgG Preparations

Increased In Vivo Antibody Activity Against Interferon α, Interleukin-1α, and Interleukin-6 After High-Dose Ig Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only